Table 2.
Pharmacological parameters of vasomotor responses to the PAR-2 agonist SLIGRL in isolated mesenteric resistance arteries (MRAs) and basilar artery (BA): effects of apixaban (APX).
| pD2 | EC50 (μM) | Emax (% tone) | P-value | |
|---|---|---|---|---|
| MRA | ||||
| Control APX |
5.15 ± 1.13 5.74 ± 0.57 |
7.02 (0.04–1211) 1.83 (0.14–24.3) |
42.9 ± 112 23.4 ± 49.0 |
<0.001 |
| MRA + L-NNA | ||||
| Control APX |
5.52 ± 0.13 5.64 ± 0.23 |
3.03 (1.70–5.40) 2.27 (0.81–6.31) |
60.8 ± 6.9 36.3 ± 14.2 |
<0.001 |
| MRA from heparin-treated | ||||
| Control APX |
5.98 ± 0.25 6.15 ± 0.30 |
1.04 (0.33–3.34) 0.71 (0.17–2.92) |
-12.3 ± 23.2 -9.9 ± 27.9 |
0.384 |
| MRA from heparin-treated + L-NNA | ||||
| Control APX |
4.06 ± 7.40 5.19 ± 2.10 |
86.4 (very wide) 6.45 (very wide) |
-146 ± 1318 -10.6 ± 174 |
0.747 |
| BA | ||||
| Control APX |
5.02 ± 0.36 5.36 ± 0.25 |
9.65 (1.84–50.6) 4.41 (1.35–14.4) |
27.6 ± 21.7 32.1 ± 11.9 |
0.108 |
| BA + L-NNA | ||||
| Control APX |
4.47 ± 0.26 4.69 ± 0.65 |
34.1 (10.0–116) 20.3 (1.00–411) |
81.7 ± 7.9 39.4 ± 32.5 |
<0.001 |
Pharmacological parameters are from non linear regression; pD2 is the negative logarithm of the concentration producing 50% of the maximum effect, EC50 is the concentration producing 50% of maximum effect (95% confidence limits are given in parenthesis), Emax is the maximum vasorelaxaton expressed as % of residual tone. Some preparations were incubated in the presence of NG-nitro-L-arginine (L-NNA, 0.1 mM) to inhibit NO biosynthesis. P-values refer to comparisons on the whole curves by two-way ANOVA.